

From: avakado Media <publications@avakado.eu>
Sent: Friday, February 17, 2012 9:34 AM
To: Hanchett, James (DPH)
Subject: Toms Top Ten this week Biogen Idec BASF and Evotec

Problems reading this email? [View in a browser](#)



Click on the arrow or [click here](#) to listen

February 17, 2012:

- [**Biogen Idec to acquire biopharma company Stromedix**](#)
- [**PhRMA says US budget proposals threaten biopharma prospects**](#)
- [**FDA approves Merck & Co glaucoma treatment**](#)
- [**BASF to invest \\$33 million in plant biotech R&D facilities at RTP**](#)
- [**Blockbuster biologics patent expiries to create strong market opportunity**](#)
- [**Endeavour increases chemical product range through AKL partnership**](#)
- [**New York Genome Center launches Alzheimer's whole genome initiative**](#)
- [**Evotec and IR Pharma form discovery alliance in respiratory diseases**](#)
- [**Chemical distributor Brenntag opens Indian head office**](#)
- [**FDA requests additional data from Novartis for expanded use of diphtheria vaccine**](#)

Brought to you by:



Tom's Top Ten sponsored by:



UNSUBSCRIBE INFORMATION

This email was sent to james.hanchett@state.ma.us, by avakado Media.

[Opt-out of any future messages here.](#)

We will respect your decision to receive no further emails from us.



This email was sent from avakado Ltd.

To stop receiving further emails, please reply to this message and include unsubscribe in the subject line.
avakado Limited is a company registered in England and Wales. Company number 04186087. VAT Registration Number: GB783470408